With today's cost structure,
The Board intends to work diligently on finding solutions to strengthen the Company's long-term financial situation.
As previously communicated, the company has applied to participate in the EIC Accelerator program. The result from the latest step in the application process was a rejection due to the company being a couple of points below the limit required to move forward in the application process. The company will appeal the decision. Though, even if the company is successful with the appeal, it is the board's assessment that further measures still need to be taken to strengthen the company's long-term financial position.
For more information, please contact:
Email: patrik.sundh@clinescientific.com
Phone: +46 0703585088
The company is listed on the Nasdaq First North Growth Market.
This information is information that
Pepparedsleden 1
AstraZeneca BioVentureHub Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About
https://news.cision.com/cline/r/cline-scientific-provides-an-update-on-the-company-s-financial-position,c3911864
https://mb.cision.com/Main/12114/3911864/2549700.pdf
(c) 2024 Cision. All rights reserved., source